stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Revenue growth
Lakefront Biotherapeutics - Sponsored ADR's revenue growth over the twelve months to 31 March 2026 was −52.2%, down 374.1 percentage points from fiscal 2025 (321.9%). Over the past ten years it has ranged from −51.3% (fiscal 2023) to 321.9% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 321.9% | 306.92 |
| FY2024 | 15.0% | 66.22 |
| FY2023 | −51.3% | (44.07) |
| FY2022 | −7.19% | (1.89) |
| FY2021 | −5.30% | 34.33 |
| FY2020 | −39.6% | (206.94) |
| FY2019 | 167.3% | 54.31 |
| FY2018 | 113.0% | 107.96 |
| FY2017 | 5.04% | (144.38) |
| FY2016 | 149.4% | 193.21 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Mar 2026 | −95.4% | (35.98) |
| Mar 2025 | −59.4% | (30.18) |
| Mar 2024 | −29.2% | (22.27) |
| Sep 2023 | −6.92% | (18.22) |
| 28 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SEPN Septerna, Inc. compare | 13,520.1% |
| BHVN Biohaven Ltd. compare | 425.2% |
| PVLA Palvella Therapeutics, Inc. compare | 146.7% |
| VCEL Vericel Corporation compare | 25.3% |
| AUPH Aurinia Pharmaceuticals Inc compare | 21.0% |
| IMNM Immunome, Inc. compare | 16.7% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | −52.2% |
| ZYME Zymeworks Inc. compare | −69.8% |
| VERA Vera Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement